参考文献9LG帝国网站管理系统

（在框内滑动手指即可浏览）9LG帝国网站管理系统

 9LG帝国网站管理系统

［1］    Valle JW，Kelley RK，Nervi B，et al.Biliary tract cancer［J］.Lancet，2021，397（10272）：428-444.9LG帝国网站管理系统

［2］    Nagino M，Ebata T，Yokoyama Y，et al.Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections［J］.Ann Surg，2013，258（1）：129-140.9LG帝国网站管理系统

［3］    Portnow LH，Kochkodan-Self  JM，Maduram A，et al.Multimodality imaging review of HER2-positive breast cancer and response to neoadjuvant chemotherapy［J］.Radiographics，2023，43（2）：e220103.9LG帝国网站管理系统

［4］    Chalabi M，Fanchi LF，Dijkstra KK，et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers［J］.Nat Med，2020，26（4）：566-576.9LG帝国网站管理系统

［5］    Marron TU，Fiel MI，Hamon P，et al.Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial［J］.Lancet Gastroenterol Hepatol，2022，7（3）：219-229.9LG帝国网站管理系统

［6］    Kuriyama N，Usui M，Gyoten K，et al.Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status［J］.BMC Cancer，2020，20（1）：405.9LG帝国网站管理系统

［7］    Matsuyama R，Mori R，Ota Y，et al.Impact of gemcitabine plus S1 neoadjuvant chemotherapy on borderline resectable perihilar cholangiocarcinoma［J］.Ann Surg Oncol，2022，29（4）：2393-2405.9LG帝国网站管理系统

［8］    Shroff RT，Javle MM，Xiao L，et al.Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial［J］.JAMA Oncol，2019，5（6）：824-830.9LG帝国网站管理系统

［9］    Choi SH，Kang I，Lee SH，et al.Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma［J］.Surgery，2023，173（2）：280-288.9LG帝国网站管理系统

［10］    Maithel SK， Javle MM，Mahipal A， et al. NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma［J］.J Clin Oncol，2022，40(suppl16):4097.9LG帝国网站管理系统

［11］    Subbiah V，Lassen U，Elena Élez，et al.Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial［J］.Lancet Oncol，2020，21（9）：1234-1243.9LG帝国网站管理系统

［12］    Ohba A， Morizane C， Kawamoto Y，et al. Trastuzumab deruxtecan(T-DXd; T-DXd)/ target=_blank class=infotextkey>DS-8201)in patients(pts)with HER2-expressing unresectable or recurrent biliary tract cancer(BTC): An investigator-initiated multicenter phase 2 study(HERB trial)［J］. J Clin Oncol，2022，40(suppl 16):4006.9LG帝国网站管理系统

［13］    Tine BAV，Hubbard JM， Mita MM， et al. A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results［J］. J Clin Oncol，2022，40(suppl 16):2583.9LG帝国网站管理系统

［14］    Ikeda S，Kudo R， Yamashita Y，et al. Primary results from JUPITER， a phase 2 basket trial of combination therapy with trastuzumab and Pertuzumab in patients with HER2-amplified solid tumors［J］. J Clin Oncol，2022，40(suppl 16):3131.9LG帝国网站管理系统

［15］    Harding JJ， Piha-Paul SA，Shah RH，et al. Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial［J］. J Clin Oncol，2022，40(suppl 16):4079.9LG帝国网站管理系统

［16］    Meric-Bernstam F，Hamilton EP，Beeram M，et al. Zanidatamab(ZW25)in HER2-expressing gastroesophageal adenocarcinoma(GEA): Results from a phase I study［J］. J Clin Oncol，2021，39(supp l3):164.9LG帝国网站管理系统

［17］    Meric-Bernstam F，Hainsworth J，Bose R，et al. MyPathway HER2 basket study: Pertuzumab(P)+ trastuzumab(H)treatment of a large，tissue-agnostic cohort of patients with HER2-positive advanced solid tumors［J］. J Clin Oncol，2021，39(suppl 15):3004.9LG帝国网站管理系统

［18］    Skoulidis F，Li BT，Dy GK，et al.Sotorasib for lung cancers with <i>KRAS</i> p.G12C mutation［J］.KRAS，2021，384（25）：2371-2381.9LG帝国网站管理系统

［19］    谢智华，程庆保，姜小清.胆道恶性肿瘤免疫治疗进展［J］.中国实用外科杂志，2021，41（9）：1056-1061.9LG帝国网站管理系统

［20］    Chen X，Wu X，Wu H，et al.Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial［J］.J Immunother Cancer，2020，8（2）：e001240.9LG帝国网站管理系统

［21］    Oh DY，Lee KH，Lee DW，et al.Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study［J］.Lancet Gastroenterol Hepatol，2022，7（6）：522-532.9LG帝国网站管理系统

［22］    III HAB，Okusaka T， Vogel A， et al. Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer［J］. J Clin Oncol，2022，40(suppl16):4070.9LG帝国网站管理系统

［23］    Vogel A，Chen L-T，He AR， et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab(D)plus gemcitabine and cisplatin(GC)in advanced biliary tract cancer(BTC)［J］. J Clin Oncol，2022，40(suppl16):4075.9LG帝国网站管理系统

［24］    Li W，Wang Y，Yu Y， et al. Toripalimab combined with gemcitabine and S-1 in the first-line treatment of advanced biliary tract cancer［J］. J Clin Oncol，2022，40(suppl 16):4081.9LG帝国网站管理系统

［25］    Jung JH，Lee HJ，Lee HS，et al.Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma［J］.World J Gastroenterol，2017，23（18）：3301-3308.9LG帝国网站管理系统

［26］    Kobayashi S，Tomokuni A，Gotoh K，et al.A RETrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer［J］.Eur J Surg Oncol，2017，43（4）：763-771.9LG帝国网站管理系统

［27］    Nakashima S，Kobayashi S，Nagano H，et al.BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer［J］.Cancer Sci，2015，106（5）：584-591.9LG帝国网站管理系统

［28］    Mansoori B，Mohammadi A，Doustvandi MA，et al.Photodynamic therapy for cancer: Role of natural products［J］.Photodiagnosis Photodyn Ther，2019，26：395-404.9LG帝国网站管理系统

［29］    Cheon YK，Lee TY，Lee SM，et al.Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma［J］.HPB (Oxford)，2012，14（3）：185-193.9LG帝国网站管理系统

［30］    Hong MJ，Cheon YK，Lee EJ，et al.Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma［J］.Gut Liver，2014，8（3）：318-323.9LG帝国网站管理系统

［31］    Stieber AC，Marino IR，Iwatsuki S，et al.Cholangiocarcinoma in sclerosing cholangitis. The role of liver transplantation［J］.Int Surg，1989，74（1）：1-3.9LG帝国网站管理系统

［32］    Meyer CG，Penn I，James L.Liver transplantation for cholangiocarcinoma: results in 207 patients［J］.Transplantation，2000，69（8）：1633-1637.9LG帝国网站管理系统

［33］    Robles R，Figueras J，Turrión VS，et al.Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma［J］.Ann Surg，2004，239（2）：265-271.9LG帝国网站管理系统

［34］    Alden ME，Mohiuddin M.The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer［J］.Int J Radiat Oncol Biol Phys，1994，28（4）：945-951.9LG帝国网站管理系统

［35］    De Vreede I，Steers JL，Burch PA，et al.Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma［J］.Liver Transpl，2000，6（3）：309-316.9LG帝国网站管理系统

［36］    Sudan D，DeRoover A，Chinnakotla S，et al.Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma［J］.Am J Transplant，2002，2（8）：774-779.9LG帝国网站管理系统

［37］    Darwish Murad S，Heimbach JK，Gores GJ，et al.Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation［J］.Liver Transpl，2013，19（5）：521-528.9LG帝国网站管理系统

［38］    Heimbach JK，Gores GJ，Haddock MG，et al.Liver transplantation for unresectable perihilar cholangiocarcinoma［J］.Semin Liver Dis，2004，24（2）：201-207.9LG帝国网站管理系统

［39］    Rea DJ，Heimbach JK，Rosen CB，et al.Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma［J］.Ann Surg，2005，242（3）：451-461.9LG帝国网站管理系统

［40］    Azad AI，Rosen CB，Taner T，et al.Selected patients with unresectable perihilar cholangiocarcinoma (pCCA) derive long-term benefit from liver transplantation［J］.Cancers (Basel)，2020，12（11）：3157.9LG帝国网站管理系统

［41］    Murad SD，Ray Kim W，Harnois DM，et al.Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers［J］.Gastroenterology，2012，143（1）：88-98.9LG帝国网站管理系统

［42］    Zaborowski A，Heneghan HM，Fiore B，et al.Neoadjuvant chemoradiotherapy and liver transplantation for unresectable hilar cholangiocarcinoma: The irish experience of the mayo protocol［J］.Transplantation，2020，104（10）：2097-2104.9LG帝国网站管理系统

［43］    Ebata T，Mizuno T，Yokoyama Y，et al.Surgical resection for Bismuth type IV perihilar cholangiocarcinoma［J］.Br J Surg，2018，105（7）：829-838.9LG帝国网站管理系统

［44］    Breuer E，Mueller M，Doyle MB，et al.Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? results from an international benchmark study［J］.Ann Surg，2022，276（5）：846-853.9LG帝国网站管理系统

［45］    Wong M，Kim J，George B，et al.Downstaging locally advanced cholangiocarcinoma pre-liver transplantation: A prospective pilot study［J］.J Surg Res，2019，242：23-30.9LG帝国网站管理系统

［46］    Twohig P，Peeraphatdit TB，Mukherjee S.Current status of liver transplantation for cholangiocarcinoma［J］.World J Gastrointest Surg，2022，14（1）：1-11.9LG帝国网站管理系统

［47］    Lunsford KE，Javle M，Heyne K，et al.Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series［J］.Lancet Gastroenterol Hepatol，2018，3（5）：337-348.9LG帝国网站管理系统

［48］    Ito T，Kuriyama N，Kozuka Y，et al.High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection［J］.BMC Cancer，2020，20（1）：209.9LG帝国网站管理系统

［49］    Yadav S，Xie H，Bin-Riaz I，et al.Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis［J］.Eur J Surg Oncol，2019，45（8）：1432-1438.9LG帝国网站管理系统

［50］    Mac Manus MP，Hicks RJ，Matthews JP，et al.Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer cORRelates with patterns of failure［J］.Lung Cancer，2005，49（1）：95-108.9LG帝国网站管理系统

［51］    Weber WA，Petersen V，Schmidt B，et al.Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use［J］.J Clin Oncol，2003，21（14）：2651-2657.9LG帝国网站管理系统